IRVING, Texas, March 24, 2026 /PRNewswire/ -- Caris Life Sciences (CAI) ® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer, is recognizing ...

A prospective trial of gastrointestinal cancer patients showed the feasibility of preemptive genetic testing for DPYD/UGT1A1 variants associated with increased chemotherapy toxicity. Genotype-guided ...

Genomic medicine leverages an individual’s genetic information to guide healthcare decisions, with drug-gene testing (also known as pharmacogenomics, or PGx) being a key application that personalizes ...

A man in his early 70s died after adjuvant chemotherapy due to fulminant gastrointestinal toxicity and bowel ischaemia linked to an undetected dihydropyrimidine dehydrogenase (DPYD) deficiency, ...

Reducing defects in the medication use process for intravesicular chemotherapy in an academic ambulatory oncology infusion center. This is an ASCO Meeting Abstract from the 2025 ASCO Quality Care ...

Please provide your email address to receive an email when new articles are posted on . Genetic testing can be accomplished for most patients with gastrointestinal cancer prior to starting ...

FDA labeling now recommends DPYD variant testing before initiating capecitabine or 5-FU, except when immediate treatment is clinically necessary. Complete DPD deficiency markedly impairs 5-FU ...